Martin Capital Advisors LLP Purchases 267 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Martin Capital Advisors LLP increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 2.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,679 shares of the medical equipment provider’s stock after purchasing an additional 267 shares during the period. Martin Capital Advisors LLP’s holdings in Lantheus were worth $724,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of LNTH. Macquarie Group Ltd. boosted its stake in Lantheus by 21.7% in the first quarter. Macquarie Group Ltd. now owns 605 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 108 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in Lantheus by 36.6% in the third quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 156 shares in the last quarter. RFG Advisory LLC boosted its stake in Lantheus by 4.4% in the third quarter. RFG Advisory LLC now owns 3,940 shares of the medical equipment provider’s stock worth $274,000 after purchasing an additional 167 shares in the last quarter. Prosperity Financial Group Inc. boosted its stake in Lantheus by 6.2% in the third quarter. Prosperity Financial Group Inc. now owns 2,967 shares of the medical equipment provider’s stock worth $206,000 after purchasing an additional 173 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in Lantheus by 3.1% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 6,217 shares of the medical equipment provider’s stock worth $432,000 after purchasing an additional 188 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LNTH shares. JMP Securities reaffirmed a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. Truist Financial reaffirmed a “buy” rating and set a $82.00 price target (up previously from $80.00) on shares of Lantheus in a research note on Monday, February 26th. StockNews.com upgraded Lantheus from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, B. Riley upped their price objective on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Stock Up 2.4 %

NASDAQ LNTH traded up $1.48 during trading hours on Friday, hitting $63.81. 798,117 shares of the company traded hands, compared to its average volume of 1,059,004. The business’s 50-day moving average is $60.66 and its 200-day moving average is $62.99. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $100.85. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The stock has a market capitalization of $4.37 billion, a price-to-earnings ratio of 13.59 and a beta of 0.53.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. Lantheus had a return on equity of 63.16% and a net margin of 25.20%. The firm had revenue of $354.00 million during the quarter, compared to analysts’ expectations of $350.44 million. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current year.

Insider Activity at Lantheus

In other news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Mary Anne Heino sold 93,863 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 94,545 shares of company stock valued at $6,169,936. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.